A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg

Completed · Phase 4 · Has a placebo group

Conditions studied: Erectile Dysfunction

In brief

This is a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel design study to evaluate effects on semen characteristics after 40 weeks of daily dosing with 20 mg tadalafil.

Key facts

Study ID

NCT00382135

Run by

Eli Lilly and Company

People needed

282

Starts

2003-11-01

Expected to finish

2005-12-01

Last updated by the study team

2007-10-25

Who can join

Age: 45 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male subjects or men with mild erectile dysfunction
• At least 45 years of age
• With specified semen characteristics.

You may not qualify if…

• Certain chronic medical conditions including cardiac disease, congestive heart failure, kidney or liver disease, cancer and HIV
• A history of certain endocrine or hormonal abnormalities
• A history of significant testicular/genital abnormalities
• Any significant reproductive abnormality identified at the start of the study.

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Bothell, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.